


### **Milestones**

- 1876 Colonel Eli Lilly opens a business to create drugs based on scientific research
- ○1995 PAREXEL IPO
- 01996 Covance IPO; PPD IPO
- 01997 Quintiles IPO
- O 1998 ICON IPO
- 1998 Quintiles becomes the first company in the industry to break the \$1 billion mark, with net revenues of \$1.19
- 2003 Quintiles is purchased by Dennis Gillings' Pharma Services Holding Inc., making Quintiles a private company
- 2008 Mergers/Acquisitions: PAREXEL and ClinPhone
- 2009 Dr. Fred Eshelman steps down as CEO of PPD
- 2010 Mergers/Acquisitions: Oracle and Phase Forward
- 2010 Sanofi and Covance sign a \$2.2 Billion deal forming a 10-year partnership
- 2011 Mergers/Acquisitions: INC and Kendle; inVentiv and i3 and Kforce and PharmaNet
- 2011 PPD is acquired by affiliates of The Carlyle Group and Hellman & Friedman, becoming a private company
- 2011 Pfizer, ICON, and PAREXEL enter a 5-year preferred provider agreement worth \$6.75 Billion
- 2012 Mergers/Acquisitions: ERT and invivodata
- 2012 Jim Ogle steps down as CEO of INC Research
- 2013 Quintiles IPO (2nd time)
- 2013 Mergers/Acquisitions: BioClinica and CoreLab; PRA and RPS: PPD and Accurian: Quintiles and Novella
- 2014 Mergers/Acquisitions: BioClinica and CCBR-SYNARC; Chiltern and Ockham; PAREXEL and ClinIntel
- 2014 INC Research and PRA IPO
- 2015 Mergers/Acquisitions: BioClinica and MediciGroup; BioClinica and Synowledge; Chiltern and Theorem; ERT and PHT; LabCorp and Covance; PAREXEL and Quantum Solutions; United Health and Optum
- 2015 Joseph Herring steps down as CEO of Covance; Dennis Gillings steps down as CEO of Quintiles

### CRO Market Size (2012-2016)

For breakdowns and future predictions, download ISR's 2015 CRO Market Size Projections 2012-2019






and

geographical

expansions.

## 1876 Colonel Eli Lilly, a farmer turned pharmacist, opened a scientific research.

R&D Era



() IPO

Beginning of Era

Major Merger/Acquisition

Major Leadership Change



1983

1984

1987

1989

1990

1992




**QUINTILES** 











# Clinical Development


Outsourcing

000






was founded in 1982.















MEDPACE

1996

COVANCE.

There are currently over 1,100 CROs in the world

### The top 5 publicly traded CROs are worth more than

IPO Era This Era is characterized by a number of CROs going public, a trend that has continued through present day.

IPO Era

### Strategic Partnerships with Pharma

2008 Eli Lilly with Covance

2010 Bristol-Myers Sauibb with Icon and PAREXEL

2010 GlaxoSmithKline with Aptuit

2010 Eli Lilly with PAREXEL

2010 Sanofi with Covance

2011 Takeda with Covance and Quintiles

2011 Bristol-Myers Sauibb with WuXi AppTec

2011 Pfizer with ICON. and PAREXEL

2012 Astellas with **INC** Research 2015 Pfizer with